Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

nirmatrelvir-ritonavir

nirmatrelvir-ritonavir
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Paxlovid TABLET, ORAL 150 mg/100 mg      
Comments:

 

Restricted to use for the treatment of mild-moderate COVID-19 patient who meet the Huntsville Hospital criteria for use.

 

Automatic stop date of 5 days.

 

This medication contains ritonavir (strong CYP3A4 inhibitor). Complete a thorough drug-drug interaction review prior to verification.

 

 

Reviewed: January 2022 (Paxlovid)

Updated: November 2023

 

Nirmatrelvir/Ritonavir (Paxlovid) Update

 

Last updated: Apr. 1, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved